A Potential Drug Target: LOC105373677 (LOC105373677 variant X2)
A Potential Drug Target: LOC105373677 (LOC105373677 variant X2)
Introduction
LOC105373677 (LOC105373677 variant X2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle, playing a crucial role in the development and progression of cancer. The LOC105373677 variant has been found to have altered expression levels in various cancer types, including breast, ovarian, and colorectal cancers. This suggests that it may be a promising target for cancer treatment. In this article, we will explore the biology of LOC105373677, its potential as a drug target, and its potential as a biomarker for cancer diagnosis and treatment.
Biochemistry and Genetics
LOC105373677 is a non-coding RNA molecule that is expressed in various cell types, including tissues, neurons, and cancer cells. It is a key regulator of the cell cycle, responsible for regulating the entry of RNA into the cytoplasm and the translation of RNA into proteins. LOC105373677 is a member of the TATA-repeat transcription factor A (TATA-A) family, which is known for its role in gene regulation and DNA replication.
LOC105373677 has been shown to play a crucial role in the regulation of the cell cycle. It is a negative regulator of the G1 phase and a positive regulator of the G2 phase. This means that when LOC105373677 is active, the cell cycle slows down and the The cell enters G1 phase; when inactive, the cell cycle speeds up and the cell enters G2 phase. This regulation is critical for the development and progression of cancer, as high-speed cell division can lead to genetic mutations that contribute to cancer.
In addition to its role in the cell cycle, LOC105373677 has also been shown to play a role in cell survival. It has been shown to regulate the expression of genes that are involved in cell survival and have been linked to the development of drug resistance cancer.
Potential Drug Target
LOC105373677 is a potential drug target due to its role in the cell cycle and its potential to regulate cell survival. Drugs that target LOC105373677 have the potential to slow down or inhibit its activity, leading to the regression of cancer cells.
One class of drugs that have been shown to target LOC105373677 is the taxanes, which are commonly used to treat breast and ovarian cancers. Taxanes work by inhibiting the activity of tubulin, which is a key protein that pulls the chromosomes into the nucleus during the cell cycle. By inhibiting tubulin activity, taxanes can slow down the cell cycle and prevent the formation of new chromosomes, leading to the regression of cancer cells.
Another class of drugs that have been shown to target LOC105373677 are the vinca alkaloids, which are commonly used to treat colorectal and other cancers. Vinca alkaloids work by inhibiting the activity of a protein called p21, which is a key regulator of the cell cycle. By inhibiting p21 activity, vinca alkaloids can slow down the cell cycle and prevent the formation of new chromosomes, leading to the regression of cancer cells.
Potential Biomarkers
LOC105373677 has also been shown to be a potential biomarker for cancer diagnosis and treatment. The altered expression of LOC105373677 has been observed in various cancer types, including breast, ovarian, and colorectal cancers. This suggests that LOC105373677 may be a useful biomarker for the diagnosis and treatment of cancer.
In addition to its potential as a drug target, LOC105373677 has also been shown to be an
Protein Name: Uncharacterized LOC105373677
The "LOC105373677 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105373677 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC105373696 | LOC105373703 | LOC105373707 | LOC105373710 | LOC105373712 | LOC105373717 | LOC105373723 | LOC105373730 | LOC105373750 | LOC105373751 | LOC105373759 | LOC105373781 | LOC105373796 | LOC105373831 | LOC105373835 | LOC105373836 | LOC105373874 | LOC105373882 | LOC105373891 | LOC105373918 | LOC105373920 | LOC105373937 | LOC105374007 | LOC105374009 | LOC105374020 | LOC105374025 | LOC105374033 | LOC105374036 | LOC105374037 | LOC105374041 | LOC105374060 | LOC105374089 | LOC105374107 | LOC105374140 | LOC105374174 | LOC105374187 | LOC105374193 | LOC105374207 | LOC105374210 | LOC105374211 | LOC105374217 | LOC105374218 | LOC105374224 | LOC105374226 | LOC105374234 | LOC105374265 | LOC105374287 | LOC105374294 | LOC105374300 | LOC105374316 | LOC105374318 | LOC105374320 | LOC105374325 | LOC105374329 | LOC105374341 | LOC105374344 | LOC105374362 | LOC105374364 | LOC105374377 | LOC105374378 | LOC105374421 | LOC105374428 | LOC105374432 | LOC105374434 | LOC105374456 | LOC105374494 | LOC105374497 | LOC105374505 | LOC105374506 | LOC105374514 | LOC105374521 | LOC105374522 | LOC105374523 | LOC105374524 | LOC105374527 | LOC105374533 | LOC105374535 | LOC105374553 | LOC105374584 | LOC105374591 | LOC105374595 | LOC105374608 | LOC105374610 | LOC105374613 | LOC105374645 | LOC105374660 | LOC105374683 | LOC105374701 | LOC105374713 | LOC105374724 | LOC105374726 | LOC105374736 | LOC105374737 | LOC105374754 | LOC105374756 | LOC105374778 | LOC105374786 | LOC105374793 | LOC105374795 | LOC105374809
